Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients
Status:
Unknown status
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety of GX-12 gene therapy combined with HAART
in the HIV-1 infected patients and to investigate the efficacy with the value of plasma viral
load and with CD4 counts and HIV-1 specific IFN-gamma expressed T-lymphocytes